We can't find the internet
Attempting to reconnect
12667.1;4 PFLS-LS
HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Résumé
HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic
Textes supplémentaires
Abstract
A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.
Participants
Rainer Riedl
Kontaktperson
rainer.riedl@zhaw.ch
ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2011-10-31
- Date de fin
- 2014-03-11
- Coûts totaux approuvés
- CHF 557507.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- P004 Biochemistry, Metabolism 100.0%